A Study to Compare Two Surgical Procedures in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

2020 ◽  
Author(s):  
Keyword(s):  
Ovarian Cancer ◽  
Surgical Procedures ◽  
Brca1 Mutations ◽  
Reduced Risk

scholarly journals Dietary fiber intake and reduced risk of ovarian cancer: a meta-analysis

2018 ◽  
Vol 17 (1) ◽  
Author(s):  
Bowen Zheng ◽  
Hui Shen ◽  
Hedong Han ◽  
Ting Han ◽  
Yonghong Qin
Keyword(s):  
Ovarian Cancer ◽  
Dietary Fiber ◽  
Meta Analysis ◽  
Fiber Intake ◽  
Dietary Fiber Intake ◽  
Reduced Risk

Impact of Previous Gynecologic Surgical Procedures on Outcomes of Non-Gynecologic Peritoneal Malignancies Mimicking Ovarian Cancer: Less Is More?

2021 ◽  
Vol 28 (5) ◽  
pp. 2899-2908 ◽  
Author(s):  
Marcello Guaglio ◽  
Dario Baratti ◽  
Shigeki Kusamura ◽  
Arthur C. V. Reis ◽  
Matteo Montenovo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Surgical Procedures ◽  
Gynecologic Surgical Procedures ◽  
Less Is More

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

1998 ◽  
Vol 16 (3) ◽  
pp. 979-985 ◽  
Author(s):  
V R Grann ◽  
K S Panageas ◽  
W Whang ◽  
K H Antman ◽  
A I Neugut
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
High Risk ◽  
Surgical Procedures ◽  
Brca2 Gene ◽  
Cost Effective ◽  
Prophylactic Surgery ◽  
Breast And Ovarian Cancer ◽  
Prophylactic Surgical Procedures

PURPOSE Young Ashkenazi Jewish women or those from high-risk families who test positive for BRCA1 or BRCA2 mutant genes have a significant risk of developing breast or ovarian cancer by the age of 70 years. Many question whether they should have prophylactic surgical procedures, ie, bilateral mastectomy and/or oophorectomy. METHODS A Markov model was developed to determine the survival, quality of life, and cost-effectiveness of prophylactic surgical procedures. The probabilities of developing breast and ovarian cancer were based on literature review among women with the BRCA1 or BRCA2 gene and mortality rates were determined from Surveillance, Epidemiology, and End Results (SEER) data for 1973 to 1992. The costs for hospital and ambulatory care were estimated from Health Care Financing Administration (HCFA) payments in 1995, supplemented by managed care and fee-for-service data. Utility measures for quality-adjusted life-years (QALYs) were explicitly determined using the time-trade off method. Estimated risks for breast and ovarian cancer after prophylactic surgeries were obtained from the literature. RESULTS For a 30-year-old woman, according to her cancer risks, prophylactic oophorectomy improved survival by 0.4 to 2.6 years; mastectomy, by 2.8 to 3.4 years; and mastectomy and oophorectomy, by 3.3 to 6.0 years over surveillance. The QALYs saved were 0.5 for oophorectomy and 1.9 for the combined procedures in the high-risk model. Prophylactic surgeries were cost-effective compared with surveillance for years of life saved, but not for QALYs. CONCLUSION Among women who test positive for a BRCA1 or BRCA2 gene mutation, prophylactic surgery at a young age substantially improves survival, but unless genetic risk of cancer is high, provides no benefit for quality of life. Prophylactic surgery is cost-effective for years of life saved compared with other medical interventions that are deemed cost-effective.

Potential for Vitamin D in the Prevention of Ovarian Cancer in Women with BRCA1 Mutations

2020 ◽  
Vol 156 (3) ◽  
pp. e17
Author(s):  
T. Pejovic ◽  
S. Joshi ◽  
S. Campbell ◽  
A. Vrvilo ◽  
F. Xu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Vitamin D ◽  
Brca1 Mutations

scholarly journals COST ANALYSIS OF TAXANE-BASED AND CISPLATIN-BASED CHEMOTHERAPY REGIMENS FOR EPITHELIAL OVARIAN CANCER IN DHARMAIS NATIONAL CANCER HOSPITAL

2017 ◽  
Vol 9 ◽  
pp. 172
Author(s):  
Bambang Dwipoyono ◽  
Septyana Choirunisa ◽  
Mardiati Nadjib ◽  
Amal C Sjaaf
Keyword(s):  
Ovarian Cancer ◽  
Cost Analysis ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
Surgical Procedures ◽  
Exploratory Study ◽  
Descriptive Analysis ◽  
Treatment Costs ◽  
Kaplan Meier ◽  
Disease Free

Objective: This exploratory study aimed to evaluate and compare the treatment costs of taxane-based versus cisplatin-based chemotherapy.Methods: This study used data from the medical and financial records of ovarian cancer patients who were admitted to Dharmais NationalCancer Hospital (RSKD) between 2008 and 2012 and subsequently underwent surgery and were treated with chemotherapy. Data were analyzedusing descriptive analysis, and a Kaplan–Meier graph was plotted to compare the survival of the patients in the taxane-based and cisplatin-basedchemotherapy groups.Results: Of 41 patients, treatment costs were available for nine patients who had undergone taxane-based chemotherapy and for 31 patients who hadundergone cisplatin-based chemotherapy. In general, surgical procedures accounted for the highest proportion of the treatment costs, followed bychemotherapy. Taxane-based chemotherapy (six cycles) was 4 times more expensive than cisplatin-based therapy. The pre- and post-chemotherapycosts of care among those treated with the taxane-based regimen were 3-4 times more expensive than those of the patients who received cisplatinbasedtreatment. The disease-free recurrence duration of the patients treated with taxane was longer (median=18 months) than that of the patientstreated with cisplatin (median=5 months).Conclusions: Taxane-based therapy increased the disease-free recurrence duration of the patients, with disease-free recurrence 3 times longer thanthat of the patients treated with the cisplatin-based regimen. However, the treatment costs of the taxane-based regimen were 4 times higher thanthose of the cisplatin-based treatment.

Women who Have Undergone a Tubal Sterilization have a Reduced Risk of Contracting Ovarian Cancer

1994 ◽  
Vol 26 (2) ◽  
pp. 90 ◽  
Author(s):  
S. Edwards
Keyword(s):  
Ovarian Cancer ◽  
Tubal Sterilization ◽  
Reduced Risk

scholarly journals BRCA1 mutations in a selected series of breast/ovarian cancer patients.

1996 ◽  
Vol 33 (9) ◽  
pp. 721-725 ◽  
Author(s):  
A M Garvin ◽  
M Spycher ◽  
M Haner ◽  
J Torhorst ◽  
H Muller ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Brca1 Mutations
Sign in / Sign up

Export Citation Format

Share Document